Internal Medicine, Gastroenterology · Detroit, MI
NPI
1326166257
Since 2007
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2799 W Grand Blvd
Detroit, MI, 48202
Phone (313) 916-2721
Groups this clinician bills Medicare through
Medicare paid, 2024
$11K
138 services
Medicare patients, 2024
52
Average age 70
Drug cost, 2024
$4.6M
744 prescriptions
Company payments, 2025
$205
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nirmal Kaur was code 99215 (office e&m - established), 55 times for 38 patients. In total Nirmal Kaur billed 138 services in 15 codes, and Medicare paid $11K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-05-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 55 | 38 | $125.97 | $6,929 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 50 | 35 | $13.12 | $656 |
By year: 2022 $24K for 825 services; 2023 $16K for 823 services; 2024 $11K for 138 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nirmal Kaur prescribed most often to Medicare patients was Stelara (Ustekinumab), with 98 prescriptions and refills. In total Nirmal Kaur wrote 744 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Stelara Ustekinumab | 98 | 151 | 18 | $2.4M |
| Mesalamine Generic | 78 | 177 | 21 | $43K |
| Azathioprine Generic | 63 | 141 | 17 | $5,386 |
| Balsalazide Disodium Generic | 51 | 129 | 15 | $12K |
| Prednisone Generic | 40 | 58 | 15 | $335 |
| Humira(Cf) Pen Adalimumab | 38 | 40 | Under 11 | $277K |
| Humira Pen Adalimumab | 33 | 33 | Under 11 | $274K |
| Xeljanz Tofacitinib Citrate | 33 | 33 | Under 11 | $159K |
| Loperamide Loperamide Hcl | 28 | 48 | Under 11 | $1,805 |
| Mercaptopurine Generic | 23 | 57 | Under 11 | $6,104 |
| Skyrizi On-Body Risankizumab-Rzaa | 23 | 41 | Under 11 | $428K |
| Budesonide Dr Budesonide | 20 | 47 | Under 11 | $2,707 |
| Omeprazole Generic | 18 | 52 | Under 11 | $382 |
| Famotidine Generic | 17 | 45 | Under 11 | $161 |
| Humira Adalimumab | 15 | 15 | Under 11 | $197K |
Brand drugs: - claims; generic drugs: 430 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nirmal Kaur $205 ($205 in general payments such as food, travel and fees) from 3 companies. The largest payer was Abbvie Inc. with $143.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.